17,261 trials
Carcinoma, Renal Cell
Primary: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs) — 215; 31; 32; 16 Participants
Chronic Myelogenous Leukemia
Primary: Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months — 74 Participants
Prostate Cancer
Primary: Median Time to Progression (TTP) — 5.1; 3.0 months — p=< 0.005
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean Pulse Rate Over (0-4 Hours) at Day 28. — -3.8; -4.8 Beat per minute (bpm)
Lymphoma
Primary: Overall Response Rate (ORR) — 67.7; 29.0; 3.3 Percentage of Participants
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Determine Maximum Tolerated Dose by the Number of Patients With a DLT Per Dose Level — 1; 0; 0; 0 Participants
Postoperative Cognitive Dysfunction
Primary: Interleukin-6 Concentration in Peripheral Blood. — 27.2; 26.6; 104; 97.7 pg/ml
Vitiligo
Primary: Percent Change in Vitiligo Area Severity Index (VASI) Score From Baseline to Week 20 — 23 percentage of change in VASI — p=0.02
Diabetes Mellitus, Type 2 · Hypertension
Primary: Change From Study Baseline Over Time in Supine Systolic Blood Pressure — 130.2; 120.1; 128.6; -6.8 mmHg
Treatment Resistant Depression
Primary: Cortical Excitability in the Dorsolateral Prefrontal Cortex (DLPFC) as Assessed by Transcranial Magnetic Stimulation-evoked Activity Detected by Electroencephalography…
Pancreatic Neoplasm
Primary: Overall Survival (OS) — 5.6; 5.1 months
Spinal Muscular Atrophy
Primary: Change From Baseline to Week 8 in Forced Vital Capacity (FVC) — -0.02; -0.03; -0.07 liters — p=0.9086
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
A/Vietnam/H5N1 Influenza Virus
Primary: Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination. — 34; 41; 34; 34 occurrences